《大行報告》瑞銀下調信達生物(01801.HK)目標價至43元 評級「買入」
瑞銀發表評級報告指,信達生物(01801.HK)去年產品收入按年增69%至40億元人民幣,超出該行預計的38億元人民幣。由於被納入國家醫保目錄,令公司受到負面影響,以致去年第四季一次性報銷庫存,故該行估計抗癌藥Tyvyt收入按年增25%。
該行將公司今明兩年每股虧損預測由1元人民幣及0.12元人民幣,下修至虧損1.74元人民幣及0.99元人民幣,2024年的每股盈利預測由1.29元人民幣調整至0.17元人民幣,並將其目標價由60元下調至43元,維持其評級為「買入」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.